iTeos to Present at the Jefferies Virtual Healthcare Conference
May 26 2021 - 6:00AM
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage
biopharmaceutical company pioneering the discovery and development
of a new generation of highly differentiated immuno-oncology
therapeutics for patients, today announced that Michel Detheux,
PhD, President and Chief Executive Officer, will present at the
Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021
at 8:00 a.m. ET.
A live webcast of the presentation will be available on the
Investors section of the company’s website at
https://www.iteostherapeutics.com. An archived replay will be
available for approximately 30 days following the presentation.
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company
pioneering the discovery and development of a new generation of
highly differentiated immuno-oncology therapeutics for patients.
iTeos Therapeutics leverages its deep understanding of cancer
immunology and immunosuppressive pathways to design novel product
candidates with the potential to fully restore the immune response
against cancer. The Company’s innovative pipeline includes two
clinical-stage programs targeting novel, validated immuno-oncology
pathways designed with optimized pharmacologic properties for
improved clinical outcomes. The initial antibody product candidate,
EOS-448, is a high affinity, potent, anti-TIGIT antibody with a
functional Fc domain, designed to enhance the anti-tumor response
through a multifaceted immune modulatory mechanism. An open-label
Phase 1/2a clinical trial of EOS-448 is ongoing in adult cancer
patients with advanced solid tumors with preliminary data
indicating preliminary clinical activity as a monotherapy and a
favorable tolerability profile. The Company is also advancing
inupadenant, a next-generation adenosine A2A receptor antagonist
tailored to overcome cancer immunosuppression. iTeos is conducting
an open-label multi-arm Phase 1/2a clinical trial of inupadenant in
adult cancer patients with advanced solid tumors. Preliminary
results indicate encouraging single-agent activity in the dose
escalation portion of the trial. iTeos Therapeutics is
headquartered in Cambridge, MA with a research center in Gosselies,
Belgium.
For further information, please contact:
Investor Contacts:Ryan BakeriTeos Therapeutics,
Inc.Ryan.Baker@iteostherapeutics.com
Media Contacts:media@iteostherapeutics.com
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Apr 2024 to May 2024
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From May 2023 to May 2024